PhRMA Lists NAFTA Renegotiation Priorities For Better US Exports
Executive Summary
US pharmaceutical industry association PhRMA has laid out what it thinks should be priorities in the upcoming renegotiation of the North American Free Trade Agreement. It wants pricing and reimbursement systems that reward innovation and improved enforcement of patentability standards.
You may also be interested in...
Could Trump’s NAFTA Renegotiation Hit Canadian Drug Price Controls?
Thanks to forthcoming NAFTA renegotiations, the US could put Canada under pressure to rethink its plans to curb excessive pricing.
Canada Plans Drug Price Reductions By Changing Reference Country List
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.
Pharma Patents Are Vulnerable In Canada As Lilly Loses NAFTA Challenge
Tribunal finds Lilly did not prove that Canada's promise utility doctrine discriminates against pharmaceutical patents; 25 pharma patents have been invalidated in past decade.